Ergoteles’s ResMed RMD Stock Holding History

Ergoteles’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,179	Closed	-$2.01M	–	677
2023 Q2	$2.01M	Buy	+9,179	New	+$2.05M	0.1%	267
2023 Q1	–	Sell	-2,421	Closed	-$504K	–	1690
2022 Q4	$504K	Buy	+2,421	New	+$532K	0.02%	695
2022 Q3	–	Sell	-1,270	Closed	-$266K	–	1919
2022 Q2	$266K	Buy	+1,270	New	+$270K	0.01%	1169
2021 Q3	–	Sell	-10,192	Closed	-$2.51M	–	1603
2021 Q2	$2.51M	Buy	+10,192	New	+$2.14M	0.06%	331
2021 Q1	–	Sell	-22,500	Closed	-$4.78M	–	1015
2020 Q4	$4.78M	Buy	+22,500	New	+$4.49M	0.16%	145

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ergoteles's RMD Position: Q3 2023 in Review

Ergoteles sold out of ResMed (RMD) in Q3 2023, closing a stake of 9,179 shares — an estimated $2.01M sold.

Ergoteles first reported a position in RMD in Q4 2020 and held it in 5 quarters. The position peaked at $4.78M in Q4 2020. 657 funds tracked by Wall St. Rank hold RMD as of Q3 2023.

Ergoteles reported no remaining ResMed position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 9,179 ResMed shares in Q3 2023, an estimated $2.01M.
Ergoteles first reported a position in ResMed in Q4 2020 and held it in 5 quarters.
Ergoteles's ResMed position peaked at $4.78M in Q4 2020.
657 funds tracked by Wall St. Rank held ResMed as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.